Caplight Directory>Companies>Aculeus Therapeutics-preview>Aculeustherapeutics


Aculeus Therapeutics

Aculeus Therapeutics

Private
ParkvilleHealthcare & Life Scienceshttp://www.aculeustherapeutics.com/

Last Round

SAFE

Sep 1, 2023

Total Funding Raised

$1.46M

Company Overview

Aculeus Therapeutics is a biotechnology company that develops small molecule drugs that modulate the immune system for the treatment of cancer and other serious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

immuno-oncologySTING agonistsmall molecule drugsdrug discoverySTING pathwaycancer therapyENPP1 inhibitorpreclinical biotechnologyinnate immunityAcute Myeloid LeukemiaAMLdrug in-licensingsemi-virtual biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aculeus Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Aculeus Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
SAFESep 1, 2023
GrantJul 23, 2021
GrantNov 9, 2020
View all Funding Rounds

Aculeus Therapeutics Investors

Notable investors and investment history

InvestorRounds
Therapeutic Innovation AustraliaGrant
SYNthesis BioVenturesSAFE
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 1, 2023

    $1.46M round led by SYNthesis BioVentures

  • Jul 23, 2021

    Received grant funding from Therapeutic Innovation Australia.

View all signals

Aculeus Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aculeus Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aculeus Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParkville
Year Founded2020
Last FundingSep 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.